Effect of hepatitis c virus infection in patients with cancer: Addressing a neglected population

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, Dimitrios P. Kontoyiannis

Research output: Contribution to journalArticle

Abstract

Background: Hepatitis C virus (HCV) infection is a neglected disease in patients with cancer. Therefore, this study examined the impact of HCV infections in these patients. Methods: The records of HCV-infected patients with cancer seen at The University of Texas MD Anderson Cancer Center (2008-2011) were reviewed. The outcomes of those who underwent HCV treatment were analyzed. Results: Of 1291 patients who had positive test results for an antibody to HCV (anti-HCV), 744 (58%) were tested for HCV-RNA; 642 (86%) of which had chronic HCV infections. Most had solid tumors (72%) and genotype-1 (G-1) infections (66%). HCV therapy was administered in 348 patients (98 of them after cancer diagnosis). Sustained virologic response (SVR) occurred in 27 (35%) of the 78 patients treated for whom outcome data were available. Compared with patients who experienced an SVR, more patients who did not were black (29% vs 4%; P=.007), had G-1 infections (72% vs 6%; P

Original languageEnglish (US)
Pages (from-to)41-50
Number of pages10
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number1
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of hepatitis c virus infection in patients with cancer: Addressing a neglected population'. Together they form a unique fingerprint.

  • Cite this

    Torres, H. A., Mahale, P., Blechacz, B., Miller, E., Kaseb, A., Herlong, H. F., Fowler, N., Jiang, Y., Raad, I. I., & Kontoyiannis, D. P. (2015). Effect of hepatitis c virus infection in patients with cancer: Addressing a neglected population. JNCCN Journal of the National Comprehensive Cancer Network, 13(1), 41-50.